May 2, 2023

Who Should Have a Radical Nephrectomy in This Era?

AUA guideline offers specific criteria for deciding between partial versus radical nephrectomy

23-URL-3767759-AUA-CQD-650×450-2-1

When the American Urological Association (AUA) published an updated guideline on “Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up” in 2021, it became the first clinical guideline to define specific criteria for determining radical versus partial nephrectomy in the management of localized renal masses and cancers.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Still, questions and controversies remain about choosing a surgical approach that balances functional outcomes with overall survival based on patient-specific factors. And while a partial nephrectomy is generally preferred in this era, when should a radical nephrectomy be considered?

“There’s nothing more controversial in the field of localized kidney cancer than decisions about who should get a partial and who should get a radical nephrectomy,” remarks Steven Campbell, MD, PhD, Chair of the AUA Renal Mass Guideline Panel and Vice Chairman of Urology at Cleveland Clinic. There are varied philosophies about management—often more related to the healthcare setting, region and surgeons’ training.

Dr. Campbell, colleague Christopher Weight, MD, and two other leaders in the field (and former fellows from Cleveland Clinic), Ithaar Derweesh, MD, and Robert Uzzo, MD, MBA, presented a course at the 2023 AUA Annual Meeting using a case-based approach to highlight the decision-making process and the updated guidelines.

What is the updated guidance?

The guideline states that radical nephrectomy should be considered whenever increased oncologic potential is suggested by tumor size, renal mass biopsy (RMB), and/or imaging features suggesting infiltrative or locally advanced features.

In this setting, radical nephrectomy is preferred if all of the following criteria are also met:

  1. The tumor is high complexity and partial nephrectomy would be challenging even in experienced hands.
  2. The patient does not have pre-existing CKD or proteinuria.
  3. The patient has a normal contralateral kidney and the new baseline estimated glomerular filtration rate (eGFR) will likely be > 45ml/min/1.73m2 even if a radical nephrectomy is performed.

If these conditions are not met, a partial nephrectomy should be considered unless there are overriding concerns about the safety or oncologic efficacy of this procedure.

Advertisement

A complicated case

A 71-year-old male presented to Cleveland Clinic’s Department of Urology with a 4.9 cm hilar right renal mass. The tumor contour was somewhat irregular and the R.E.N.A.L. nephrometry score was 10. He had a history of coronary artery disease and a stent placed six years prior.

Based on imaging, the location of the tumor, near the hilum, would make a partial nephrectomy more technically challenging, and its irregular shape raised concerns for aggressive disease. The team considered the following:

  1. Partial nephrectomy
  2. Radical nephrectomy
  3. Split renal function (SRF) and RMB to obtain further information before deciding

They ultimately elected to obtain a SRF to estimate the GFR of the contralateral kidney and an RMB to get more information about the tumor before making a decision.

“A partial nephrectomy would be a no-brainer if it was a solitary kidney. But it’s not and the contralateral kidney appears normal. Still, a partial nephrectomy is generally preferred because it preserves more function,” says Dr. Campbell. “But does it translate to better overall survival in this patient where the other kidney appears normal? Given the complexities with this case, we decided to obtain more information before surgery.”

Using computerized software to measure parenchymal volume based on imaging — an analysis that has largely replaced nuclear renal scans at our center — the team identified a baseline GFR of 83 and an SRF of 53% and 47% on the left and right, respectively. The RMB indicated a clear cell, grade 3 malignancy, suggesting that the tumor biology might be on the more aggressive end of the spectrum.

Dr. Campbell uses a simple calculation to estimate the patient’s new baseline GFR following the radical nephrectomy: global GFR (83) x SRF contralateral x 1.25. The 1.25 coefficient is the average amount of renal functional compensation observed in adults after radical nephrectomy.

Advertisement

“Based on this, we proceeded with a radical nephrectomy, because our data suggested that the patient should end up with a GFR of 55, and he met all other criteria for radical nephrectomy,” he explains. Data show that reduced survival becomes a concern when a patient’s GFR is expected to fall below 45ml/min/1.73m2.

Case outcomes

MIS radical nephrectomy confirmed that the malignancy was clear cell, pathological stage T3a (protruding into a branch vein), grade 4 with rhabdoid features, and all margins were negative. The patient’s post-operative GFR was 52, proximate to the team’s estimation of 55.

Overall, Dr. Campbell is pleased with their decision and the overall outcome. Four years later, the patient still shows no evidence of disease and maintains a GFR of > 50.

Utilizing radical nephrectomy when it’s truly needed

Though the tumor wasn’t large, it was — by all accounts — aggressive. The irregular contour on the imaging and RMB suggested increased oncologic potential. The SRF analysis revealed a normally functioning contralateral kidney, and an NBGFR estimation suggested it would maintain function following radical nephrectomy. In this case, Dr. Campbell explains, a partial nephrectomy could have put the patient at risk for more unfavorable outcomes.

“The goal is utilizing radical nephrectomy for patients who really need it, while reducing its overutilization. The AUA guideline — the only one that provides a granular description of criteria for radical nephrectomy — can be used to determine whether it is indeed the optimal treatment,” he concludes.

Related Articles

URL_Pavelko_3777858_Urology_Dr. Lundy in Clinic_04-26-23_LDJ
January 30, 2024
Starting the Conversation About Male Infertility

Male factors play a role in about half of all infertility cases, yet men often are not evaluated

URL_Mould_3793308_Dr. Hadley Wood with patient at Q8_04-07-23_LD
December 1, 2023
Cleveland Clinic Urologist To Lead Esteemed Medical Journal

Hadley Wood, MD, shares her vision as the new editor-in-chief of Urology

sacral neuromodulation lead
October 9, 2023
Optimizing Outcomes in Sacral Neuromodulation for Overactive Bladder

Study leverages data from the ROSETTA trial

male urological anatomy
August 21, 2023
Aquablation Therapy Offers Alternative Approach for Benign Prostatic Hyperplasia

More on the procedure and the institutional experience

23-URL-3769861 CQD 650×450
June 22, 2023
The Complex Bacterial Colonization of Penile Implants

Study analyzes device biofilms, establishes basis for future developments

805x-inset-Damaser
June 19, 2023
First-in-Human Study Shows Safety, Feasibility of UroMonitor

What it could mean for the future of ambulatory monitoring for bladder conditions

21-URL-2271032 CQD 650×450
May 4, 2023
Microbiome, Mycobiome Differences Seen in Overactive Bladder

Could it unlock the potential for new approaches to treatment?

Ad